Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Researcher profile - 09/11/2015 Boutros_Michael_2015_2.jpg

    Michael Boutros – from the study of social gene networks to the management of the DKFZ

    Deregulation of cell signalling pathways is a major driver of cancer. Prof. Dr. Michael Boutros has pioneered the development of new methods for the analysis of genetic interactions in such complex networks. He has been acting Chairman and Scientific Member of the Management Board of the German Cancer Research Center (DKFZ) since September 1st 2015.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/michael-boutros-from-the-study-of-social-gene-networks-to-the-management-of-the-dkfz
  • Press release - 03/11/2015 07777_de.jpg

    CureVac raises $110 Million in a private placement

    CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
  • Vaccine development - 02/11/2015 Valerie_Herrmann.jpg

    A new vaccine could prevent influenza epidemics

    Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
  • Article - 26/10/2015 Photo of Stefan Hell

    Ultrafast STED nanoscopy

    Nobel Laureate Stefan Hell and his team at the German Cancer Research Center in Heidelberg have achieved yet another milestone in super-resolved optical microscopy. The team have developed an ultrafast STED (stimulation emission depletion) nanoscope that now makes it possible to study molecular processes and transport processes in living cells in millisecond time steps.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ultrafast-sted-nanoscopy
  • Article - 12/10/2015 Mechanismus_Lenalidomid_Kroenke2.jpg

    Ulm researchers are writing a new chapter of the thalidomide story

    Thalidomide, which was sold in Germany in the late 1950s under the trade name Contergan, is mainly known for having caused one of the biggest pharmaceutical scandals in Germany. However, what was once a sleeping pill is increasingly being used as an immunomodulatory drug for treating tumours of the haematopoietic system, something that is not yet widely known. Dr. Jan Krönke is the head of a junior research group at Ulm University Hospital…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/ulm-researchers-are-writing-a-new-chapter-of-the-thalidomide-story
  • Article - 30/09/2015 Haworth formula of 6-deoxy-6-sulphoglucose.

    New synthesis method produces compound for use in tumour medicines

    Very few people have ever heard of the chemical compound sulphoquinovose. This natural substance is nevertheless found in a large variety of foods. Sulphoquinovose has been playing an increasing role in cancer research, which is why demand for the compound is constantly growing. With this in mind, researchers from a company called MCAT GmbH from Konstanz are working on the development a method to synthesise larger quantities of sulphoquinovose…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-synthesis-method-produces-compound-for-use-in-tumour-medicines
  • Article - 28/09/2015 The photo shows a man in a white lab coat. He has short hair and is smiling into the camera.

    Breast cancer: a few millilitres of urine to diagnose the disease early

    It would be phenomenal news if it turned out that breast cancer could be detected by way of urine samples. Treating physicians would be able to use conspicuous test results to begin further examinations as quickly as possible along with therapy if necessary. Prof. Dr. Elmar Stickeler and his team from the Freiburg University Medical Centre have developed a method that identifies the composition of microRNAs in urine. They were able to predict…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/breast-cancer-a-few-millilitres-of-urine-to-diagnose-the-disease-early
  • Article - 24/09/2015 ESEQuant_LR3.jpg

    New test system for detection of HPV-related oral cavity cancers

    The number of people suffering from oral or oropharyngeal cancer is rising steadily. The major cause of these cancers is human papillomaviruses (HPV) that colonise the oral cavity, where they are difficult to detect. QIAGEN Lake Constance GmbH from Stockach, in cooperation with Abviris Deutschland GmbH, has developed a new test system to improve the detection of oral HPV. This new system enables rapid and reliable quantitative detection of…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/new-test-system-for-detection-of-hpv-related-oral-cavity-cancers
  • Press release - 26/08/2015 Immatics Logo

    Immatics Biotechnologies GmbH - new alliances and launch of Immatics US, Inc.

    MorphoSys and Immatics Biotechnologies Enter Strategic Alliance in Immuno-oncology. Furthermore Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-biotechnologies-gmbh-new-alliances-and-launch-of-immatics-us-inc
  • Article - 27/07/2015 Zender_Lars_Prof.jpg

    Looking for the Achilles’ heel of the tumour

    Although medicines that inhibit the growth of cancer cells are available, the prognosis for patients with solid tumours is generally still rather poor. The reason for this is that tumour cells develop resistance to therapy during treatment, and the tumour can continue to grow. However, tumours are vulnerable – if only more robust medicines were available. Prof. Dr. Lars Zender, senior physician and head of the Division of Translational…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-achilles-heel-of-the-tumour
  • Article - 20/07/2015 23437_de.jpg

    Liver cell carcinoma: reducing tumour burden – increasing life expectancy

    Liver cell carcinoma or hepatocellular carcinoma (HCC) is one of the most malignant human cancers. The disease arises from chronic damage to the liver, usually caused by virus- or alcohol-related liver cirrhoses. Liver tumours are considered difficult to treat, but there is evidence that they actually trigger an immune response in the body. Prof. Dr. Robert Thimme from Freiburg University Medical Centre is seeking to understand this effect and…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/liver-cell-carcinoma-reducing-tumour-burden-increasing-life-expectancy
  • Article - 13/07/2015 23413_de.jpg

    CureVac and Boehringer Ingelheim - two strong partners forge cancer immunotherapy alliance

    Two German companies have teamed up to become a driving force in the immunotherapy of lung carcinomas. CureVac GmbH from Tübingen and Boehringer Ingelheim are working together on the development of a therapy for non-small cell lung cancer using CureVac’s vaccine CV9202. The drug is based on messenger RNA and will be used in combination with other therapies with the goal of fighting the tumour on several fronts.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/curevac-and-boehringer-ingelheim-two-strong-partners-forge-cancer-immunotherapy-alliance
  • Article - 06/07/2015 23430_de.jpg

    Blood stem cells deliver drugs to brain tumours

    The brain is the central switchboard in our body. Professor Ghazaleh Tabatabai’s work focuses specifically on the brain and the fight against uncontrolled proliferation of brain tumours. In May 2014, she was appointed professor in the newly established Interdisciplinary Division of Neuro-Oncology at the University of Tübingen and head of the Clinical and Experimental Neuro-Oncology research group at the Hertie Institute for Clinical Brain…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/blood-stem-cells-deliver-drugs-to-brain-tumours
  • Article - 29/06/2015 23436_de.jpg

    3D cell culture model for more efficient tumour research

    The development of anti-cancer drugs is a lengthy process because results obtained in vitro in the laboratory often differ from what then occurs in a living organism. A group of researchers led by Prof. Dr. Margareta Müller at the Furtwangen University of Applied Sciences is therefore developing a new cell culture model that adjusts in vitro to real conditions.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/3d-cell-culture-model-for-more-efficient-tumour-research
  • Article - 29/06/2015 15921_de.jpg

    The transition from acute to chronic pain

    Prof. Dr. Rohini Kuner and fellow scientists from Heidelberg have shown that a protein that inhibits an enzyme produced by immune cells protects nerve cells from chronic hypersensitivity to neuropathic pain. Kuner is also the spokesperson of a new collaborative research centre in Heidelberg that is receiving funding from the German Research Foundation totalling over 12 million euros. The centre is seeking to find the reasons why acute pain…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/the-transition-from-acute-to-chronic-pain
  • Article - 26/05/2015 23292_de.jpg

    Does too much beef and cow’s milk cause cancer?

    The large number of breast and colon cancer cases might be due to viruses that are taken up with beef and dairy products. This is the provocative thesis of Nobel Laureate Harald zur Hausen who previously linked HPV with cervical cancer. In addition to epidemiological evidence, zur Hausen and his team have also provided experimental evidence to substantiate his thesis.

    https:////www.gesundheitsindustrie-bw.de/en/article/news/does-too-much-beef-and-cows-milk-cause-cancer
  • Article - 26/05/2015 The photo shows two scientists looking into the camera.

    Novel effect of B-Raf inhibitors against bowel cancer discovered

    Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
  • Article - 18/05/2015 The figures shows a model of a spherical parvovirus. Parvoviruses are non-enveloped viruses, which makes them rather resistant against external influences.

    Parvoviruses can destroy brain tumours

    Parvoviruses such as H-1PV have been shown to selectively attack and destroy human cancer cells. However, they are unable to replicate in healthy human cells. A preliminary clinical trial is currently being carried out to assess the suitability of parvoviruses for treating malignant brain cancer. Scientists from the German Cancer Research Center (DKFZ) have now discovered the cause of the selective effect of H-1PV. The finding helps identify…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/parvoviruses-can-destroy-brain-tumours
  • Article - 11/05/2015 Microscopic image of MTSS1 expression.

    Lung cancer: MTSS1 is a putative marker of tumour progression and metastatic disease

    Lung cancer is one of the most common malignant diseases and one of the leading causes of cancer-related deaths worldwide. 90% of all lung cancer cases in men and 80% in women are due to long-term exposure to tobacco smoke. In Germany, around 140 new cases are diagnosed every day, and 50,000 people die of lung cancer every year. PD Dr. Gian Kayser, senior consultant in the Department of Clinical Pathology at Freiburg University Medical Centre,…

    https:////www.gesundheitsindustrie-bw.de/en/article/news/lung-cancer-mtss1-is-a-putative-marker-of-tumour-progression-and-metastatic-disease
  • Press release - 29/04/2015 The logo shows the words "cytena, Single Cells on Demand".

    cytena received EUR 1.1 million of seed capital from HTGF and a private investor

    cytena GmbH, headquartered in Freiburg, has developed a device called cy-Clone to separate single cells. A consortium made up of a private investor and High-Tech Gründerfonds (HTGF), will provide EUR 1.1 million of seed capital. cytena GmbH will use this capital injection primarily to launch its product and to expand its marketing and distribution activities.

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/cytena-received-eur-11-million-of-seed-capital-from-htgf-and-a-private-investor
  • Overview

    Basic research

    The latest articles, press releases and dossiers on basic research in Baden-Württemberg

    https:////www.gesundheitsindustrie-bw.de/en/article/research
  • Overview

    Red biotechnology

    The latest articles, press releases and dossiers on red biotechnology in Baden-Württemberg

    https:////www.gesundheitsindustrie-bw.de/en/article/biotech
  • Overview

    Pharmaceutics

    The latest articles, press releases and dossiers on pharmaceutics in Baden-Württemberg

    https:////www.gesundheitsindustrie-bw.de/en/article/pharma
  • Dossier - 13/04/2015 In Germany, young girls can now protect themselves from cervical cancer. (Photo: NCI)

    Boosting the immune system can improve cancer prevention and treatment

    The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.

    https:////www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
  • Press release - 01/04/2015 23155_de.jpg

    Migrating immune cells promote nerve cell demise in the brain

    The slow death of dopamine-producing nerve cells in a certain region of the brain is the principal cause underlying Parkinson's disease. In mice, it is possible to simulate the symptoms of this disease using a substance that selectively kills dopamine-producing neurons. Scientists from the German Cancer Research Center (DKFZ) have now shown for the first time in mouse experiments that after this treatment, cells of the peripheral immune…

    https:////www.gesundheitsindustrie-bw.de/en/article/press-release/migrating-immune-cells-promote-nerve-cell-demise-in-the-brain

Page 6 / 29

sb_search.block.search_result.other.pages

  • eine Seite vor
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 29
  • eine Seite zurück
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • sb_theme_biopro.domain.mdr-ivdr
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2021
Website address: https://www.gesundheitsindustrie-bw.de/en/search